Documented batches Public COA verification Research use only Quality standards
Primal Platform
← Back to all peptide profiles
Cyclic peptide Approval and post-marketing data Human data available

Peptide database · P-032

Setmelanotide

Setmelanotide; RM-493; Imcivree

Setmelanotide is a cyclic MC4R agonist used in authorised medicines for selected genetically defined forms of obesity.

01

Molecular profile

Molecular profile

Molecule class
Cyclic peptide
Origin
Synthetic analogue
Primary target system
Melanocortin-4-Rezeptor
Development stage
Authorised active substance
Structure note

Zyklisches Peptidanalogon und selektiver MC4R-Agonist.

02

Mechanism and signalling

Mechanism and signalling

Activation of hypothalamic MC4R targets a central node in hunger and energy homeostasis.

03

Scientific classification

Scientific classification

This profile maps Setmelanotid to the research areas metabolism, rare_disease. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.

Metabolism and energy regulation

Pathways related to glucose homeostasis, appetite, energy expenditure and body composition.

Rare diseases and precision medicine

Peptide therapeutics for molecularly defined rare diseases and specialised treatment concepts.

04

Evidence base

Approval and post-marketing data

PreclinicalEarly human dataClinical dataPhase IIPhase IIIApproval and post-marketing data

Approval trials concern molecularly defined rare diseases. Findings do not generalise to common obesity.

05

Regulatory status

Authorised in the EU/multiple markets

Authorised in the EU/multiple markets

The active substance is used in authorised medicines in multiple jurisdictions. Authorisations apply only to defined products, indications, quality standards and conditions of use.

06

Safety and use notice

No dosing or administration recommendation

The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.

07

Sources and registries

Sources and registries